Tags

Type your tag names separated by a space and hit enter

[Probiotics have a limited role in the treatment of inflammatory bowel disease].
Ned Tijdschr Geneeskd 2012; 156(40):A5206NT

Abstract

Probiotics are frequently prescribed for the treatment of inflammatory bowel disease (IBD). However, supporting evidence for the use of probiotics in IBD is scarce. Most studies are limited by design or do not show that probiotic treatment is effective. Only a few randomised controlled trials have demonstrated any beneficial effect of probiotic use in IBD; namely, the use of VSL#3 in patients with pouchitis and ulcerative colitis. So far, the efficacy of probiotics in the treatment of Crohn's disease has not been clearly demonstrated. Furthermore, issues pertaining to their mechanisms of action, dosages and dosing intervals, safety, and health insurance coverage are currently unresolved. Given the limited body of evidence of their efficacy from controlled trials and the many unanswered questions on probiotic treatment, we recommend following the evidence obtained from well-designed randomised controlled trials and only prescribing probiotic treatment (e.g. VSL #3) for the prevention of pouchitis and the treatment of patients with mildly active ulcerative colitis.

Authors+Show Affiliations

University of Alberta, Center of Excellence for Gastrointestinal Inflammation and Immunity Research, Edmonton, Canada.No affiliation info available

Pub Type(s)

English Abstract
Journal Article

Language

dut

PubMed ID

23031240

Citation

Dieleman, Levinus A., and Frank Hoentjen. "[Probiotics Have a Limited Role in the Treatment of Inflammatory Bowel Disease]." Nederlands Tijdschrift Voor Geneeskunde, vol. 156, no. 40, 2012, pp. A5206.
Dieleman L, Hoentjen F. [Probiotics have a limited role in the treatment of inflammatory bowel disease]. Ned Tijdschr Geneeskd. 2012;156(40):A5206.
Dieleman, L., & Hoentjen, F. (2012). [Probiotics have a limited role in the treatment of inflammatory bowel disease]. Nederlands Tijdschrift Voor Geneeskunde, 156(40), pp. A5206.
Dieleman L, Hoentjen F. [Probiotics Have a Limited Role in the Treatment of Inflammatory Bowel Disease]. Ned Tijdschr Geneeskd. 2012;156(40):A5206. PubMed PMID: 23031240.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Probiotics have a limited role in the treatment of inflammatory bowel disease]. AU - Dieleman,Levinus A, AU - Hoentjen,Frank, PY - 2012/10/4/entrez PY - 2012/10/4/pubmed PY - 2012/12/10/medline SP - A5206 EP - A5206 JF - Nederlands tijdschrift voor geneeskunde JO - Ned Tijdschr Geneeskd VL - 156 IS - 40 N2 - Probiotics are frequently prescribed for the treatment of inflammatory bowel disease (IBD). However, supporting evidence for the use of probiotics in IBD is scarce. Most studies are limited by design or do not show that probiotic treatment is effective. Only a few randomised controlled trials have demonstrated any beneficial effect of probiotic use in IBD; namely, the use of VSL#3 in patients with pouchitis and ulcerative colitis. So far, the efficacy of probiotics in the treatment of Crohn's disease has not been clearly demonstrated. Furthermore, issues pertaining to their mechanisms of action, dosages and dosing intervals, safety, and health insurance coverage are currently unresolved. Given the limited body of evidence of their efficacy from controlled trials and the many unanswered questions on probiotic treatment, we recommend following the evidence obtained from well-designed randomised controlled trials and only prescribing probiotic treatment (e.g. VSL #3) for the prevention of pouchitis and the treatment of patients with mildly active ulcerative colitis. SN - 1876-8784 UR - https://www.unboundmedicine.com/medline/citation/23031240/[Probiotics_have_a_limited_role_in_the_treatment_of_inflammatory_bowel_disease]_ L2 - http://www.ntvg.nl/A5206 DB - PRIME DP - Unbound Medicine ER -